title: Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia.
abstract: Etoposide (125 mg/m2/d) and carboplatin (200 mg/m2/d) were administered by continuous 5-day intravenous infusion to 10 patients with relapsed or refractory acute leukemia (7 ANLL, 1 ALL, 2 blast crisis of CGL). No complete or partial response was observed despite dose-limiting toxicity characterized by severe diarrhea in four patients and neutropenic colitis in two additional cases. We cannot recommend the present schedule of drug administration for the treatment of acute leukemia.
authors.affiliation: Department of Internal Medicine, Mayo Foundation, Rochester, Minnesota 55905, USA.
authors.forename: L
authors.initials: L
authors.lastname: Letendre
authors.forename: P
authors.initials: P
authors.lastname: Noel
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
authors.forename: L A
authors.initials: LA
authors.lastname: Solberg
authors.forename: D A
authors.initials: DA
authors.lastname: Gastineau
authors.forename: H C
authors.initials: HC
authors.lastname: Hoagland
mesh_terms: D000293:Adolescent; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007938:Leukemia / Q000188:drug therapy*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D016879:Salvage Therapy
chemical_list: D005047:Etoposide; D016190:Carboplatin